RxDoctor Payments Data

Pedro Calderon Artero, MD

Interventional Cardiology · Tyler, TXNPI 1568751196

Payments from drug & device makers

$884in general payments, 2019–2025

Across 52 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$219
  • Medtronic$127
  • Boston Scientific$101
  • Pfizer$62
  • Amgen$59
  • Irhythm Technologies, Inc.$47
  • plus $269 from 11 others

What the payments were for

  • Food & beverage$884100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$884 in reported general payments places this provider in the 5th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$209,332
Medicare patients
1,504
Services billed
3,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$225,213
EntrestoSacubitril/Valsartan183$202,505
Repatha SureclickEvolocumab188$155,862
FarxigaDapagliflozin Propanediol74$78,103
JardianceEmpagliflozin65$49,772
Praluent PenAlirocumab54$29,744
XareltoRivaroxaban25$16,997
BrilintaTicagrelor19$15,906
Rosuvastatin Calcium463$7,745
Repatha SyringeEvolocumab13$7,051
Atorvastatin Calcium493$6,621
Ranolazine ErRanolazine65$5,980
Icosapent Ethyl16$5,591
Metoprolol Succinate320$5,572
Losartan Potassium404$5,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$225,213242 claims
NovartisEntresto$28$202,505183 claims
AstraZenecaFarxiga, Brilinta, Symbicort$23$96,711107 claims
Boehringer IngelheimJardiance$21$49,77265 claims
Johnson & JohnsonXarelto$34$16,99725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →